fluorouracil has been researched along with Carcinoma, Ductal in 17 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 9.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes." | 7.76 | Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010) |
| "A 47-year-old woman with metastatic breast cancer developed acute pancreatitis while receiving capecitabine." | 7.72 | Capecitabine-induced pancreatitis. ( Jones, KL; Valero, V, 2003) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 6.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 5.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| " A total of 283 women with metastatic breast cancer were initially enrolled in a randomised multicentre trial comparing docetaxel to sequential methotrexate-fluorouracil (MF) in advanced breast cancer after anthracycline failure." | 5.11 | Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. ( Ahlgren, J; Amini, RM; Blomqvist, C; Poikonen, P; Sjöström, J; Villman, K, 2005) |
| "We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes." | 3.76 | Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010) |
| "A 47-year-old woman with metastatic breast cancer developed acute pancreatitis while receiving capecitabine." | 3.72 | Capecitabine-induced pancreatitis. ( Jones, KL; Valero, V, 2003) |
| " A postmenopausal woman was treated for stage II breast cancer with a modified radical mastectomy and adjuvant cyclophosphamide, doxorubicin, and 5-flurouracil followed by tamoxifen for 5 years." | 3.72 | Raloxifene rebound regression. ( Dosik, M; Kaufman, R, 2004) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 2.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "The diagnosis was made as right breast cancer (T4c, N3c, M1, and stage IV)." | 1.35 | [A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies]. ( Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K, 2009) |
| "This is the first study investigating neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with chemotherapy in patients with breast cancer." | 1.33 | Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. ( Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mokrim, M | 1 |
| Aftimos, PG | 1 |
| Errihani, H | 1 |
| Piccart-Gebhart, M | 1 |
| Iguchi, T | 1 |
| Uchida, J | 1 |
| Nakamura, T | 1 |
| Kawamura, M | 1 |
| Wakasa, K | 1 |
| Nakatani, T | 1 |
| Aoyagi, H | 1 |
| Kaneko, J | 1 |
| Makinose, T | 1 |
| Someno, Y | 1 |
| Katsuta, E | 1 |
| Saguchi, M | 1 |
| Okubo, K | 1 |
| Hamada, S | 1 |
| Sekine, T | 1 |
| Sato, T | 1 |
| Sugihara, K | 1 |
| Maejima, S | 1 |
| Vrdoljak, E | 1 |
| Mise, BP | 1 |
| Lukić, B | 1 |
| Curić, Z | 1 |
| Bosković, L | 1 |
| Tica, I | 1 |
| Ferreira, A | 1 |
| Vieira, C | 1 |
| Rodrigues, A | 1 |
| Pereira, D | 1 |
| Rodrigues, H | 1 |
| Dávila, C | 1 |
| Bento, S | 1 |
| Basu, S | 1 |
| Baghel, NS | 1 |
| Jones, KL | 1 |
| Valero, V | 1 |
| SILVA, AR | 1 |
| SMART, CR | 1 |
| ROCHLIN, DB | 1 |
| van Kuilenburg, AB | 1 |
| Meinsma, R | 1 |
| Zonnenberg, BA | 1 |
| Zoetekouw, L | 1 |
| Baas, F | 1 |
| Matsuda, K | 1 |
| Tamaki, N | 1 |
| van Gennip, AH | 1 |
| Tominaga, T | 1 |
| Kimura, M | 1 |
| Asaga, T | 1 |
| Yoshida, M | 1 |
| Awane, H | 1 |
| Koyama, H | 1 |
| Takatsuka, Y | 1 |
| Mitsuyama, S | 1 |
| Ikeda, T | 1 |
| Ogita, M | 1 |
| Aoyama, H | 1 |
| Sano, M | 1 |
| Abe, R | 1 |
| Nishi, T | 1 |
| Wada, T | 1 |
| Danno, M | 1 |
| Toi, M | 1 |
| Takashima, S | 1 |
| Dosik, M | 1 |
| Kaufman, R | 1 |
| Poikonen, P | 1 |
| Sjöström, J | 1 |
| Amini, RM | 1 |
| Villman, K | 1 |
| Ahlgren, J | 1 |
| Blomqvist, C | 1 |
| Cho, JY | 1 |
| Paik, YH | 1 |
| Chang, YS | 1 |
| Lee, SJ | 1 |
| Lee, DK | 1 |
| Song, SY | 1 |
| Chung, JB | 1 |
| Park, MS | 1 |
| Yu, JS | 1 |
| Yoon, DS | 1 |
| Roddiger, SJ | 1 |
| Kolotas, C | 1 |
| Filipowicz, I | 1 |
| Kurek, R | 1 |
| Kuner, RP | 1 |
| Martin, T | 1 |
| Baltas, D | 1 |
| Rogge, B | 1 |
| Kontova, M | 1 |
| Hoffmann, G | 1 |
| Pollow, B | 1 |
| Zamboglou, N | 1 |
| Zorzi, D | 1 |
| Abdalla, EK | 1 |
| Pawlik, TM | 1 |
| Brown, TD | 1 |
| Vauthey, JN | 1 |
| Cottu, PH | 1 |
| Asselah, J | 1 |
| Lae, M | 1 |
| Pierga, JY | 1 |
| Diéras, V | 1 |
| Mignot, L | 1 |
| Sigal-Zafrani, B | 1 |
| Vincent-Salomon, A | 1 |
| Puglisi, F | 1 |
| Cardellino, GG | 1 |
| Crivellari, D | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
1 review available for fluorouracil and Carcinoma, Ductal
| Article | Year |
|---|---|
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
4 trials available for fluorouracil and Carcinoma, Ductal
| Article | Year |
|---|---|
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Ch | 2004 |
Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle | 2005 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
12 other studies available for fluorouracil and Carcinoma, Ductal
| Article | Year |
|---|---|
Effective combined chemotherapy for prostatic ductal adenocarcinoma: continuous venous infusion of 5-fluorouracil and low-dose consecutive cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal; Cisplatin; Fluorouracil; Humans; | 2003 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2009 |
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; C | 2010 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcino | 2011 |
Capecitabine-induced pancreatitis.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; D | 2003 |
CHEMOTHERAPY OF BREAST CANCER.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; F | 1965 |
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
Topics: Amidohydrolases; Amino Acid Sequence; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neo | 2003 |
Raloxifene rebound regression.
Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphami | 2004 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2006 |
Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Hepa | 2006 |
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |